# A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

> **NCT00002136** · PHASE1 · COMPLETED · sponsor: **Daiichi Pharmaceuticals**

## Conditions studied

- Sarcoma, Kaposi
- HIV Infections

## Interventions

- **DRUG:** Tecogalan sodium

## Key facts

- **NCT ID:** NCT00002136
- **Lead sponsor:** Daiichi Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002136, "A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*